Lonafarnib
Zokinvy (lonafarnib) is a small molecule pharmaceutical. Lonafarnib was first approved as Zokinvy on 2020-11-20. It is known to target GTPase NRas, GTPase HRas, GTPase KRas, and protein farnesyltransferase subunit beta. Zokinvy's patent is valid until 2024-07-26 (FDA).
Trade Name | Zokinvy |
---|---|
Common Name | Lonafarnib |
Indication | |
Drug Class | Farnesyl transferase inhibitor |